<DOC>
	<DOCNO>NCT01581918</DOCNO>
	<brief_summary>Nausea vomit common problem cancer patient . Half experience symptom course disease , either cancer treatment1 . They rank patient two bad adverse effect cancer chemotherapy cause negative impact patient 's functional , emotional , social nutritional status quality life2,3 . Nowadays , wide variety antiemetic agent available prevention treatment CINV . In scenario , three class play critical role : Selective 5-HT3-receptor antagonist - approve clinical practice early 1990s , revolutionize management CINV represent effective agent treatment acute emesis - , Corticosteroids - unknown mechanism action , effective administer single agent patient receive chemotherapy low emetic potential beneficial use combination antiemetic agent , potentiate anti-emetic efficacy acute delayed symptom - neurokinin 1 receptor antagonist - also effective acute delay emesis , restrict utility daily clinical practice high cost .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Carbamazepine Prevention Chemotherapy-induced Nausea Vomiting</brief_title>
	<detailed_description>Meanwhile lot study three class drug , effort do reach high control rate CINV different drug . In scenario , randomize phase II placebo-controlled trial Cruz et . al . demonstrate Gabapentin raise chemotherapy-induced nausea vomit control associate Dexametason Ondasetron , suggest could cost-effective alternative neurokinin 1 receptor antagonists9 , although , know , ` comparative study gabapentin aprepitant . Guttuso et al demonstrate open clinical study antiemetic effect gabapentin chemotherapy-induced acute ( within 24hs ) delay onset ( day 2-5 ) nausea vomit breast cancer patient refractory emesis10 . Tan e col show high complete delay nausea vomit control rate olanzapine vs. aprepitant , association palonosetron dexametason highly moderately emetogenic potential chemotherapy11 . Navari e cols n't find similar result although comparison may do , since maintenance anti-emetic treatment different studies12 . In case report , Strohscheer I . &amp; Borasio GD show complete control refractory nausea vomit one patient meningeal carcinomatosis treat Carbamazepine13 . Carbamazepine available anticonvulsant largely used Brazil . The aim study evaluate role Carbamazepine prevention nausea vomit induced moderate highly emetogenic chemotherapy .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>old 18 year old start moderate highly emetogenic chemotherapy define contain cisplatin , doxorrubicin epirrubicin high dose 60mg/m2 , 50mg/m2 e 50mg/m2 respectively must sign informed consent form . previuos chemotherapy low emetogenic antiemetic potential disagree n't sign consent form .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>